Choroideremia

Choroideremia (pronounced kuh‑ROY‑der‑EE‑mee‑ah) is a rare, inherited eye disease that slowly robs people—mostly males—of their sight. It starts with night‑blindness in childhood, then eats away at side vision (peripheral vision) until only a narrow “tunnel” of central vision remains, and finally causes total blindness in later adult life. Under a microscope, three critical layers at the back of the eye—the retina, the retinal‑pigment epithelium (RPE) and the choroid—progressively thin and die because their cells cannot recycle vital proteins properly. A single gene on the X‑chromosome called CHM is always to blame; when that gene is faulty, the eye cannot make enough Rab escort protein‑1 (REP‑1), a molecular “courier” that helps shuttle other proteins to the right place inside a cell. Without REP‑1, retina cells malfunction, starve, and disappear, and sight fades away. MedlinePlus

Think of every cell in your retina as a busy shipping yard. Tiny cargo carriers called Rab‑GTPases need a helper (REP‑1) to get “address labels” that tell them where to dock. When CHM mutations wipe out REP‑1, Rab carriers drift aimlessly, cell recycling stalls, waste piles up, and the cell’s powerhouses (mitochondria) overheat. Over decades this slow “garbage strike” kills first the RPE, then photoreceptors, and finally the choroidal blood vessels that feed them. Eye‑specific damage is severe because the rest of the body has a backup protein (REP‑2); the retina does not. EyeWiki

---

Recognised clinical types (phenotypic patterns)

Although all cases arise from CHM mutations, doctors see several practical patterns. Understanding the pattern helps set expectations and select the best tests.

1. Classic male phenotype – The textbook form: boys show night‑blindness by age 7‑10, tunnel vision in the teens and 20s, legal blindness in mid‑life.

2. Female carrier phenotype – Women with a single mutated X‑chromosome often look normal in daylight yet may show subtle pigment “pepper‑sprinkling” on eye exam, patchy areas on autofluorescence imaging, and mild night or glare problems after age 40.

3. Early‑onset severe variant – Rare nonsense or large‑deletion mutations trigger rapid cell loss so that visual field constriction is obvious in primary school and central vision disappears before age 30.

4. Central‑island variant – Some patients keep a small island of healthy macula into their 50s, retaining reading vision even though the periphery is blank.

5. Atypical female‑dominant disease – Very uncommon X‑inactivation “skewing” or X‑autosome translocations let the faulty CHM dominate in most retinal cells of a woman, producing a picture almost as bad as the male classic form. EyeWiki

---

Causes

Because every case begins with a gene error, the “causes” below describe the many ways CHM can break down or the secondary cascades that accelerate retinal death.

1. Nonsense mutation in CHM – A premature “stop‑signal” in the DNA cuts the recipe for REP‑1 short; no working protein is made.

2. Missense mutation – A single “misspelled” DNA letter swaps one amino‑acid for another, producing a REP‑1 that folds badly and is quickly destroyed.

3. Frameshift insertion or deletion – Extra or missing DNA letters shift the reading frame, garbling every amino‑acid downstream and yielding useless REP‑1.

4. Splice‑site mutation – Errors at intron‑exon junctions cause the cell to skip or include the wrong segments; REP‑1 loses critical domains.

5. Large genomic deletion – Whole exons—or the entire CHM gene—are missing, abolishing REP‑1.

6. Gene duplication – Copy‑and‑paste of CHM segments confuses the cell’s editing machinery, resulting in non‑functional protein.

7. Chromosomal translocation – CHM breaks off and re‑attaches to another chromosome; nearby “on/off” switches no longer work.

8. X‑autosome translocation in females – The only active X carries the mutant CHM, so carriers express disease.

9. Altered REP‑1 prenylation pocket – Subtle mutations hinder its ability to attach the lipid “tail” that Rab proteins need to anchor to membranes.

10. Defective Rab‑protein prenylation cascade – Even if REP‑1 is partly present, faulty helper enzymes can leave Rab proteins unprocessed.

11. Oxidative stress overload – Dying RPE cells release free radicals, damaging neighbouring photoreceptors faster than genetics alone predicts.

12. Mitochondrial dysfunction – Energy factories in RPE cells falter when protein trafficking stops, accelerating cell suicide (apoptosis).

13. Micro‑vascular dropout – Loss of choriocapillaris blood flow deprives outer retina of oxygen and nutrients, hastening degeneration.

14. Chronic neuro‑inflammation – The retina’s immune cells (microglia) become overactive as debris accumulates, releasing toxic cytokines.

15. Secondary cone‑stress pathways – Even though rods die first, stressed cones up‑regulate death genes (e.g., caspase‑3), bringing forward central vision loss. EyeWikiMedlinePlus

---

Symptoms

1. Night‑blindness (nyctalopia) – Dim classrooms, twilight streets or cinema aisles suddenly feel pitch‑black because rod photoreceptors are failing first. Cleveland Clinic

2. Peripheral “shadow zones” – Bumping into doorframes or people when walking because the outer visual field is shrinking.

3. Tunnel vision – By the late teens many describe looking through a narrow straw; side vision is almost gone.

4. Glare sensitivity – Bright sunlight scatters inside the damaged retina, making outdoor activities uncomfortable.

5. Poor visual acuity – Reading small print or recognizing faces becomes harder as central cones begin to starve.

6. Colour‑vision loss – Especially greens and reds fade because cone cells lose pigment.

7. Difficulty adapting between light and dark – Transition from bright to dim rooms takes several painful minutes.

8. Reduced contrast sensitivity – Pale text on pastel backgrounds or steps without strong edges become invisible.

9. Depth‑perception errors – Abnormal visual fields make stairs or curbs appear flatter than they are.

10. Eventually, legal blindness – Most men reach severe vision impairment (20/200 or worse) by their 50s if untreated. Cleveland Clinic

---

Diagnostic tests

A. Physical‑exam–based

1. Standard visual‑acuity chart – Measures clarity of central vision; gradual drop alerts clinicians to macular involvement.

2. Confrontation visual‑field test – A quick office trick where the doctor wiggles fingers in different quadrants to flag early field loss.

3. Pupil light reflex examination – Sluggish or asymmetric constriction suggests optic nerve or extensive retinal damage.

4. Dilated fundus examination – Looking through the pupil with an ophthalmoscope reveals pale, “moon‑crater” patches where retina and choroid have melted away. EyeWiki

B. Manual/bedside functional tests

5. Amsler grid – A chequerboard held at reading distance; wavy or missing lines betray macular thinning.

6. Dark‑adaptometry – Sitting in a dark booth, the patient presses a button when they first see faint lights; prolonged detection time confirms rod failure.

7. Colour‑vision plates (Ishihara or Hardy‑Rand‑Rittler) – Missed numbers reveal cone pigment loss long before central acuity drops.

C. Laboratory & pathological tests

8. Targeted CHM gene sequencing – The gold standard: identifies the exact DNA error, distinguishes choroideremia from look‑alikes such as retinitis pigmentosa. Cleveland Clinic

9. Multiplex ligation‑dependent probe amplification (MLPA) – Detects large deletions or duplications invisible to routine sequencing.

10. Prenylation activity assay in cultured fibroblasts – Measures how well Rab proteins get their lipid tails; near‑zero activity confirms REP‑1 loss.

11. Carrier testing for female relatives – Blood or saliva sequencing pinpoints heterozygous women for counselling and trial eligibility.

D. Electrodiagnostic tests

12. Full‑field electroretinography (ERG) – Electrodes record the retina’s electrical flash response; in choroideremia the rod signal vanishes early, cone signal later.

13. Multifocal ERG (mfERG) – Maps electrical responses across small retinal zones, highlighting surviving “islands” of function.

14. Pattern visual‑evoked potentials (pVEP) – Measures the optic nerve’s response to checkerboard patterns; reduced amplitude mirrors macular damage.

15. Electro‑oculography (EOG) – Gauges RPE health by tracking eye‑movement‑related voltage shifts; a low Arden ratio supports widespread RPE loss. EyeWiki

E. Imaging tests

16. Fundus photography – High‑resolution colour pictures document progressive bleaching of the fundus and islands of preserved tissue.

17. Fundus autofluorescence (FAF) – Highlights lipofuscin in RPE cells; dark patches show where cells have died, bright rims outline active degeneration.

18. Optical coherence tomography (OCT) – Cross‑section scans resemble “optical ultrasound,” revealing thinning of outer retinal layers and collapse of choroid.

19. OCT‑angiography (OCT‑A) – Visualises choriocapillaris blood flow without dye; gaps match visual‑field scotomas.

20. Fluorescein or indocyanine‑green angiography – Intravenous dye films leaking or absent choroidal vessels, confirming vascular dropout pattern unique to choroideremia. Cleveland ClinicEyeWiki

Non-Pharmacological Treatments

Below you’ll find 20 practical, research-backed ways to protect remaining vision and enhance daily life. Each item includes a short purpose statement and the basic mechanism in plain English.

Exercise-Oriented Therapies

1. Orientation-and-Mobility (O&M) Training – Specialists teach safe cane skills, spatial listening, and smartphone GPS use so patients keep moving confidently even as side vision shrinks. By reinforcing alternative sensory pathways, O&M lowers fall risk and social isolation. Midwest Low Vision

2. Adaptive Aerobic Exercise – Activities like stationary cycling or swimming build cardiovascular health without heavy visual demands. Better blood flow nourishes retinal cells and boosts overall fitness.

3. Low-Vision Strength Workouts – Elastic-band or body-weight routines maintain muscle tone; stronger limbs improve balance when peripheral cues fade.

4. Oculomotor “Eye-Movement” Drills – Brief, daily tracking tasks (following a target across a screen) keep extra-ocular muscles supple and may enhance the brain’s use of residual fields.

5. Balance & Proprioception Sessions – Simple one-leg stands or wobble-board practice help the inner ear and joints compensate for lost visual input.

6. Outdoor Light-Adapted Walking – Early-morning strolls wearing wrap-around UV-filter glasses provide safe sunlight, natural circadian cues, and mild exercise.

7. Water-Fitness Classes – Pools reduce impact; instructors use tactile or audio prompts so even late-stage patients enjoy full-body workouts.

Mind–Body Approaches

1. Mindfulness-Based Stress Reduction (MBSR) – Guided meditations reduce anxiety, which otherwise worsens perceived visual disability; calmer cortisol levels also protect retinal micro-circulation.
2. Yoga for Vision Loss – Modified poses paired with breathing slow heart rate, stretch stiff neck muscles, and promote mental resilience during progressive sight change.
3. Progressive Muscle Relaxation – Systematic tensing and easing of muscle groups lessens tension headaches common in people straining to use restricted visual fields.
4. Guided Imagery & Visualization – Audio scripts encourage the brain’s visual cortex to stay active, potentially helping neural plasticity.
5. Tai Chi – Slow, memorized motions practiced with tactile markers improve postural sway and proprioceptive feedback.
6. Breath-Control (Pranayama) Exercises – Five-minute, twice-daily sessions stabilize autonomic tone and may mildly dilate retinal vessels.

Educational / Self-Management Strategies

1. Low-Vision Rehabilitation Therapy – Certified therapists fit high-add reading spectacles, reverse telescopes, or electronic magnifiers so patients keep reading, working, and driving (where legal).
2. Assistive Technology Training – Screen-reader software, audio books, and voice assistants substitute for print, sustaining employment and education.
3. Genetic Counselling – Families learn inheritance patterns and reproductive choices; early identification enables timely clinical-trial enrollment.
4. Peer-Support Groups – Sharing adaptive tips lowers depression and sparks creative problem-solving.
5. Nutrition Education – Dietitians outline antioxidant-rich foods (leafy greens, fish oils) that complement supplement regimens listed later.
6. Sleep-Hygiene Coaching – Dark-room rituals and blue-light filters protect fragile circadian rhythms disturbed by night-blindness.
7. Home-Safety & Lighting Audits – Simple tweaks (high-contrast stair edges, motion-sensor lamps) cut accident rates as peripheral vision contracts.

---

Pharmacological or Biologic Drugs Under Study

No medicine is yet approved specifically for choroideremia; all options below are off-label or investigational and must be discussed with a retinal specialist.

1. Timrepigene Emparvovec (AAV2-REP1 Gene Therapy) – One-time sub-retinal injection (≈1 × 10¹¹ vector genomes per eye). Class: adeno-associated viral vector. Designed to deliver a working CHM gene; aims to halt photoreceptor loss. Key side effects: transient ocular inflammation, cataract progression. Nature

2. 4D-110 (Intravitreal AAV Capsid Variant) – Single intravitreal dose (dose-escalation trials testing 3 × 10¹¹–1 × 10¹² vg). Class: engineered AAV gene therapy; may reach entire retina without surgery. Adverse events so far limited to mild vitritis. ClinicalTrials.govir.4dmoleculartherapeutics.com

3. Acetazolamide 250 mg orally 2 × daily – Carbonic-anhydrase inhibitor used off-label to reduce cystoid macular edema sometimes seen in CHM; watch for tingling, fatigue, kidney stones.

4. Topical Dorzolamide 2 % eye drops 3 × daily – Same class, local delivery; helpful if oral side-effects limit acetazolamide use.

5. Oral Vitamin A Palmitate 15,000 IU nightly – May improve rod pigment recycling; requires close liver and lipid monitoring. ICHGCPctv.veeva.com

6. Lutein 10 mg + Zeaxanthin 2 mg daily – Carotenoid antioxidants concentrate in macula, potentially buffering oxidative stress; mild yellow skin hue possible.

7. Omega-3 DHA 1,000 mg daily – Anti-inflammatory fatty acid that integrates into photoreceptor membranes; can thin blood slightly.

8. Topical Corticosteroid (Loteprednol 0.5 % qid for 1 week taper) – Used episodically for postoperative inflammation after gene-therapy surgery.

9. Intravitreal Triamcinolone 4 mg – Investigated for persistent macular edema; cataract and pressure rise risks.

10. Experimental Neuroprotective Peptide (e.g., Brimonidine intravitreal implant) – Slow-release insert every 3–6 months; aims to prolong retinal ganglion-cell survival; still early-phase.

---

Dietary Molecular Supplements

(Always coordinate with your physician before starting supplements.)

1. Lutein 10 mg/day – Functions as a macular antioxidant “filter,” absorbing blue light and quenching free radicals; mechanism: lipid-soluble carotenoid accumulates in photoreceptor outer segments.

2. Zeaxanthin 2 mg/day – Works synergistically with lutein; similar protective mechanism.

3. Omega-3 DHA/EPA 1 g/day – Integrates into retinal disc membranes, improving fluidity and lowering inflammatory cytokines.

4. Vitamin A Palmitate 15,000 IU/day – Supplies chromophore for rhodopsin regeneration; mechanism: supports retinoid cycle in rods.

5. Vitamin C 500 mg twice daily – Water-soluble antioxidant scavenging reactive oxygen species.

6. Vitamin E (d-alpha-tocopherol) 400 IU/day – Lipid-phase antioxidant protecting cell membranes; excessive doses may thin blood.

7. Zinc Gluconate 25 mg/day – Cofactor for retinal dehydrogenase enzymes; note that excess zinc may upset copper balance.

8. Alpha-Lipoic Acid 300 mg/day – Regenerates other antioxidants and chelates iron; may improve mitochondrial function.

9. Curcumin 500 mg twice daily with black-pepper extract – Polyphenol down-regulates NF-κB driven inflammation; fat-soluble so best with meals.

10. Resveratrol 250 mg/day – Activates SIRT-1 pathways linked to photoreceptor survival; mechanism extrapolated from animal retinal studies.

---

Regenerative / Stem-Cell or Gene-Editing Approaches

1. Timrepigene Emparvovec (AAV2-REP1) – Described above; mechanism: functional CHM gene expression restores prenylation in RPE and photoreceptors. Nature

2. 4D-110 – Intravitreal gene therapy designed to cross the internal limiting membrane; same functional goal with less-invasive delivery. ClinicalTrials.govir.4dmoleculartherapeutics.com

3. Lenti-REP1 (Lentiviral Vector) – Early-phase studies deliver REP-1 via lentivirus; longer transgene capacity may permit broader expression, but integration risk is higher.

4. CRISPR-Corrected Autologous iPSC-RPE Sheets – Patient skin cells reprogrammed, CHM mutation repaired, then differentiated into RPE and transplanted under macula; aims to replace dying support cells. PMC

5. Photoreceptor Precursor Transplantation – iPSC-derived rods/cones injected sub-retinally to replenish lost photoreceptors; mechanism: graft integrates synaptically with host bipolar cells. PMC

6. Exosome-Based REP-1 Delivery – Lab studies package functional protein or mRNA in extracellular vesicles; potential repeat-dose, non-viral therapy still in preclinical phase.

---

Surgical Procedures

1. Sub-Retinal Gene-Therapy Micro-Injection – Pars-plana vitrectomy creates a tiny retinal bleb; surgeon injects vector beneath fovea. Benefits: one-time disease-modifying potential, minimal systemic exposure.

2. Cataract Extraction with High-Add Intraocular Lens – Removes opacified lens accelerated by steroid use or aging; high-plus optics enlarge image on small remaining retina.

3. Epiretinal Prosthesis (e.g., Argus II) – Electrode array placed on retinal surface transmits camera signals; may restore light perception in end-stage cases.

4. Macular Translocation Surgery – Surgeon rotates intact macula onto healthier choroid; rarely done but can move functioning photoreceptors away from chorioretinal atrophy.

5. Autologous RPE-Choroid Patch Graft – Section of peripheral RPE-choroid transplanted under fovea; provides new blood supply and support for central photoreceptors.

---

Practical Prevention Strategies

1. Early Genetic Testing & Counselling – Confirms diagnosis, identifies carriers, and guides family planning.

2. Protect Eyes from Excess UV & Blue Light – Wear wrap-around sunglasses and brimmed hats outdoors.

3. Maintain Antioxidant-Rich Diet – Emphasize leafy greens, berries, and fish.

4. Avoid Smoking and Second-Hand Smoke – Tobacco accelerates oxidative retinal damage.

5. Control Systemic Diseases – Keep blood pressure, lipids, and diabetes in check to maintain ocular circulation.

6. Use Safe-Lighting at Home – High-contrast strips on stairs, motion-sensor night-lights.

7. Schedule Annual Dilated Exams – Retinal specialists can detect treatable complications early.

8. Update Driving Assessments – Follow legal guidelines as visual field narrows to protect yourself and others.

9. Engage in Regular Physical Activity – Supports vascular health that nourishes the retina.

10. Stay Informed on Clinical Trials – Progress is rapid; qualified patients may access sight-saving therapies.

---

When Should You See a Doctor?

Seek prompt ophthalmic care if you notice sudden flashes, new floaters, hazy vision, a curtain-like shadow, or rapid drop in central acuity—signs that could indicate retinal tear, detachment, macular edema, or post-surgical inflammation. Regular six- to twelve-month visits are essential even without new symptoms because many complications are silent until advanced.

---

“Do’s and Don’ts” for Daily Living

1. Do wear high-quality sunglasses outdoors.

2. Do practice O&M cane skills before vision shrinks further.

3. Do keep antioxidant supplements in a pill organizer to ensure adherence.

4. Do join a low-vision peer group for emotional support.

5. Do discuss clinical-trial eligibility with your retinal specialist.

6. Don’t ignore subtle changes in night or peripheral vision.

7. Don’t drive once your horizontal field drops below legal limits.

8. Don’t smoke; if you do, enroll in cessation programs.

9. Don’t skip safety rails or adequate lighting at home.

10. Don’t rely on unverified online “cures” that promise miracle vision restoration.

---

Frequently Asked Questions (FAQs)

1. Is choroideremia the same as retinitis pigmentosa (RP)?
   No. Both involve night-blindness and tunnel vision, but RP is genetically heterogeneous; CHM specifically lacks the REP-1 enzyme.

2. Can women go blind from choroideremia?
   Carriers often keep central vision for life, but a minority develop severe loss—regular exams are crucial.

3. At what age does sight typically begin to fail?
   Night-vision problems often start in childhood; central vision usually remains until the 40s–50s.

4. Will gene therapy restore lost sight?
   Current trials aim mainly to slow further loss; modest gains in light sensitivity have been reported, but outcomes vary. Nature

5. How long does AAV gene therapy last?
   Because AAV DNA remains largely episomal, expression may persist many years, but lifetime durability is still under study.

6. Is vitamin A safe for everyone?
   High doses can damage liver or bones; always monitor blood tests and avoid if pregnant.

7. Do blue-light blocking glasses help?
   They reduce glare and retinal oxidative load, but do not stop structural degeneration alone.

8. Are stem-cell cures available now?
   Autologous iPSC-RPE sheets are still experimental and only in early trials for retinal diseases. PMC

9. Can exercise make vision worse?
   Moderate exercise improves circulation and is beneficial; avoid contact sports that risk eye trauma.

10. Will cataract surgery speed vision loss?
    No; it often improves brightness perception, but post-op inflammation must be controlled, especially after gene-therapy eyes.

11. Is CHM always inherited from the mother?
    Yes; it is X-linked. Fathers with CHM transmit the defective X only to daughters (carriers), not sons.

12. How often should I update my eyeglass prescription?
    Annually, because refractive changes and lens yellowing can mask the true state of retinal function.

13. Are there diet plans specifically for choroideremia?
    No single diet, but Mediterranean-style eating provides antioxidants and healthy fats.

14. Can I fly after gene-therapy surgery?
    Usually yes after gas bubble resorbs (about 1–2 weeks), but follow your surgeon’s timetable.

15. Where can I find trial information?
    ClinicalTrials.gov lists open studies; search “choroideremia” and discuss options with your doctor.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 16, 2025.